A Novo Nordisk analysis of 194 patients on Ro's telehealth platform found that those who switched from weekly obesity injections (Wegovy or Eli Lilly's Zepbound) to the oral Wegovy pill lost an additional 4% of body weight — about 8.8 pounds — over three months, starting from an average of 221 pound